in their effects on enzymatic activity and, at least in some instances (such as the substitution of arginine for glycine at position 37 [G37R]), the mutant enzyme reSummary tains full specific activity . In lymphocytes from individuals with familial ALS, there is only High levels of familial Amyotrophic Lateral Sclerosis a modest reduction in the abundance of the G37R SOD1 (ALS)-linked SOD1 mutants G93A and G37R were prepolypeptide, and the mutant polypeptide is fully active viously shown to mediate disease in mice through an . Moreover, SOD1 null mice live to acquired toxic property. We report here that even low adulthood and to date have not been documented to levels of another mutant, G85R, cause motor neuron develop motor neuron disease (Reaume et al., 1996) . disease characterized by an extremely rapid clinical Finally and most convincingly, lines of transgenic mice progression, without changes in SOD1 activity. Initial expressing either G93A or G37R human SOD1 have eleindicators of disease are astrocytic inclusions that vated SOD1 activity levels (4-to 14-fold that of nonstain intensely with SOD1 antibodies and ubiquitin and transgenic littermates) and develop progressive hind-SOD1-containing aggregates in motor neurons, fealimb weakness and muscle wasting between 4 and 6 tures common with some cases of SOD1 mutantmonths of age. In these animals, motor neurons degenmediated ALS. Astrocytic inclusions escalate markerate, often exhibiting vacuoles that have been interedly as disease progresses, concomitant with a preted to originate from the Golgi and endoplasmic reticdecrease in the glial glutamate transporter (GLT-1).
ulum in cell bodies of G93A mice (Dal Canto and Gurney, Thus, the G85R SOD1 mutant mediates direct damage 1994) and from degenerating mitochondria in dendrites to astrocytes, which may promote the nearly synchroor axons of G37R mice . Disease in nous degeneration of motor neurons.
G93A and G37R mice requires high levels of mutant SOD1. In addition, one line of mice expressing a mutation in mouse SOD1 that is homologous in position to the Introduction familial ALS-linked G85R mutation has been reported to cause motor neuron loss and rapidly progressing Amyotrophic Lateral Sclerosis (ALS) is a progressive disease without elevating SOD1 activity (Ripps et al., neurodegenerative disorder resulting from degeneration 1995) . and death of lower motor neurons in the brain stem
In this report, we document that human SOD1 mutant and spinal cord, leading to generalized weakness and G85R can cause dominantly inherited, rapidly progresmuscle atrophy (Delisle and Carpenter, 1984; Banker, sive disease in spite of accumulation to very low levels 1986). Of ALS cases, 5%-10% are familial, inherited in mice (0.2-1.0 ϫ endogenous mouse SOD1) and within an autosomal dominant manner. The mechanisms out any increase or decrease in overall SOD1 activity. leading to degeneration of motor neurons in familial and Despite latencies of Ͼ8 months, once initiated, motor sporadic ALS are not clearly understood. The discovery neuron loss proceeds nearly synchronously with ‫%04ف‬ (Rosen et al., 1993) of dominant, missense mutations of large spinal motor neuron axons degenerating over (Ͼ45 such mutations are now known) in the metalloena 2 week disease duration. Moreover, prominent SOD1-zyme Cu-Zn superoxide dismutase (SOD1) as the pricontaining inclusions in astrocytes appear prior to clinimary cause of 15%-20% of familial ALS cases has focal signs and increase markedly in abundance during cused attention on how mutants in this ubiquitously disease progression, implicating astrocytes as primary expressed enzyme cause selective death of motor neurons. Because SOD1 activity is believed to play a crucial targets for mutant-SOD1 mediated damage. Moreover, the glial glutamate transporter (GLT-1), the major gluta- series of known amounts of purified human erythrocyte SOD1 ( Figures 1B and 1C , lanes 1-4). The amount of G85R mutant was determined using an anti-peptide with endogenous SOD1, whereas accumulated levels of polyclonal antibody specific for human SOD1 ( Figure 2B , lanes 1-6) revealed 1B, lanes 5-13) was measured using a polyclonal antithat G85R SOD1 was undetectable in red blood cells body generated against a peptide identical in mouse ( Figure 2B , lanes 2-4), whereas high levels of human and human SOD1. Phosphorimaging of these and a set SOD1 were present in transgenic mice expressing wildof parallel blots (analyzing samples from four animals type or G37R mutant SOD1 (e.g., 4 ϫ the endogenous each for lines 148, 164, and 87 and two animals for SOD1 level in mice expressing wild-type human SOD1; each of the other lines) revealed that mutant SOD1 in Figure 2B , lane 1). Analysis of the levels of the endogetransgenic lines (lanes 6-13) accumulated to 0.02% of nous and G85R mutant SOD1 in spinal cords from line total protein ‫%02ف(‬ of endogenous mouse SOD1) for 148 revealed that levels of mutant SOD1 were unthe lowest expressing line (line 46; Figure 1C , lane 11) changed at 1 and 3 months of age but were elevated and 0.1% of total protein (equivalent to mouse SOD1) by 2-fold at end-stage disease, whereas levels of endogin the highest expressing line (line 148, Figure 1C , lane enous mouse SOD1 were unaltered in these G85R 9). Using an antibody specific for mouse SOD1, levels transgenics ( Figure 2C , middle lane) and in nonof endogenous mouse SOD1 were unchanged in all lines transgenic littermates ( Figure 2C , bottom lane). While (compare normal mouse in Figure 1D , lane 5 with we cannot exclude a potential contribution of increased transgenic mice in Figure 1D , lanes 6-13).
RNA transcription or RNA stability to the increased levels RNA blotting for levels of transgene-encoded RNA of G85R at end stage, these data strongly suggest that (not shown) revealed a level of RNA in the highest G85R degradation of mutant G85R SOD1 is slowed as the expressing line (line 148; Figure 1C , lane 9), indistinanimals age. guishable from that in a mouse line previously reported to accumulate FALS-linked mutant G37R to 5 ϫ the level G85R SOD1 Does Not Influence Overall of mouse SOD1 . The lower level of SOD1 Activity accumulated G85R (relative to that of G37R in mice with
To test whether the G85R mutant affects levels of activity comparable levels of mutant encoding SOD1 mRNAs) of the endogenous SOD1 subunits, spinal cord extracts confirms in a more in vivo context the finding from transwere electrophoresed in native gels, and activity was fection experiments with cultured cells (Borchelt et al., measured by the ability of SOD1 to inhibit the conversion 1995) that the G85R polypeptide has a shorter half life of nitro blue tetrazolium to formazan. In three mice from than G37R.
line 148, SOD1 activity was similar to that in a control Immunoblotting of extracts of various tissues, includanimal (compare Figure 2D , lanes 5-7 with lane 4). Since ing spinal cord, cortex, brain stem, cerebellum, muscle, the G85R subunit has previously been shown to be comliver, and kidney (Figure 2A ), revealed that G85R accupletely inactive in this gel assay , mulated in all these tissues, as seen earlier for mutant the constant level of activity indicates that activity of G37R . Using an antibody recognizing the endogenous mouse SOD1 was not altered, consishuman and mouse SOD1 (Figure 2A ), mutant SOD1 accumulates in both kidney and liver to levels comparable tent with the constant level of mouse SOD1 polypeptide and a nontransgenic littermate (lane 5) were electrophoresed on 15% SDS-PAGE gels and immunoblotted using rabbit polyclonal antibodies that recognize (B) a common epitope shared between human and mouse SOD1, (C) an epitope on human but not mouse SOD1, or (D) an epitope specific for mouse SOD1. All antibodies were detected with 125 I-labeled protein A. A series of 2-fold dilutions of purified human SOD1 was immunoblotted in parallel (lanes 1-4) to provide quantitation standards. (E) Levels of G85R mutant SOD1 versus endogenous wild-type mouse SOD1 determined by phosphorimaging of the blots in (B) and ( ( Figure 1D ) and the observation that mutant SOD1 does developed hindlimb paralysis and muscle atrophy (Table  1 ; Figure 1F ). The age of onset varied between 8-10 not exert a dominant negative effect in vitro . The G85R polypeptide retains some activity months for the highest expressing line (line 148-G85R levels 100% of endogenous SOD1) and 12-14 months in vivo (as reported for the mutant protein assayed in solution after expression with a baculovirus vector [Fujii for the lowest expressing line (line 74-G85R levels 20% of endogenous SOD1), but after onset, all mutant lines et al., 1995] or in yeast (Corson et al., unpublished data] ), but even if fully active in vivo, its low abundance cannot showed a uniformly rapid progression of disease. The initial sign was weakened grip strength in one hindlimb, raise overall SOD1 activity significantly over that in nontransgenic control mice. Although protein levels of muwhich spread very rapidly to the other hindlimb and then to the forelimbs. Mice were completely paralyzed within tant SOD1 increase at end-stage disease ( Figure 2C ), endogenous mouse SOD1 activity in transgenic mice is 2 weeks after initial signs. In a few mice, disease advanced so rapidly that hind-and forelimbs appeared not altered with age (compare Figure 2D , lanes 5-7 and 9-11 for transgenic animals with similar samples from affected simultaneously. In some animals, the hindlimbs were so severely affected that the mice were unable to control mice in lanes 4 and 8).
feed ( Figure 1F ) and were sacrificed before any signs of forelimb involvement. One line (line 46) expressing G85R SOD1 Causes a Late-Onset, Rapidly Progressive Motor Neuron Disease the lowest level of mutant SOD1 ( Figure 1C , lane 11) did not develop clinical signs by 15 months. Each of the eight lines of G85R mice was examined at different ages for clinical signs. In seven lines, mice
Ten animals in line 148 were closely observed from the time of the earliest obvious clinical signs. In all cases, within 2-3 days after appearance of hindlimb weakness, the affected hindlimb became severely paralyzed, and the limb assumed a distorted posture ( Figure 1F ). Within 3-4 days, the other hindlimb displayed obvious weakness, and 1-2 weeks after onset, these animals were so severely immobilized that they were unable to feed.
Evolution of Pathology: The Earliest Lesions Are SOD1-Containing Inclusions in Astrocytes and More Diffuse SOD1/Ubiquitin-Containing Aggregates in Motor Neurons
To delineate the evolution of pathology, we examined spinal cords from G85R SOD1 mice (line 148) that develop clinical signs between 8-10 months of age. No abnormalities were identified in mice Ͻ6 months of age. However, at 6 months (Table 1) , early abnormalities of two types were identified. First, round inclusions with a dense core and a clear peripheral halo were revealed by hemotoxylin and eosin (H and E) staining ( Figure 3B ). These inclusions resemble the Lewy bodies that are present in the cytoplasm of pigmented neurons in the substantia nigra and locus ceruleus in Parkinson's disease (Galloway et al., 1996) , but in the G85R mice, these initial "Lewy body-like" inclusions were in astrocytes, not neurons, as indicated by immunoreactivy with antibodies to the astrocyte-specific glial fibrillary acidic protein (GFAP) ( Figure 3A) . Inclusions in astrocytes became more abundant as disease progressed. By end stage ( Figure 3C ), when SOD1 increased 2-fold in spinal cord extracts ( Figure 2C ), there was a marked increase in astrocytosis ( Figure 3C , open arrow) and a ‫-01ف‬fold increase in inclusions. Almost all of these were confirmed by staining with antibodies to GFAP ( Figure 3C ) and absence of staining with neurofilament antibodies ( Figures 3D and 3E , arrows) to be within astrocytes. Similar astroglial inclusions were prominent not only in line 148 but also in three other G85R lines examined in detail (lines 103, 164, and 87). A striking finding was that throughout disease, both core and periphery of inclusions ( Figure 3F ) were highly immunoreactive with an antibody recognizing a common epitope in human and mouse SOD1 ( Figure 3G, inset) . Only the periphery of these inclusions (both in young animals or at end stage) was immunoreactive for GFAP ( Figures  3A and 3C ) or ubiquitin ( Figure 3F, inset) antibodies. SOD1-immunoreactive inclusions were also observed tous material covered with small granules ‫02ف(‬ nm in (B) Immunoblots with an antibody specific for human SOD1 of exdiameter; Figures 4B and 4C ) in which organelles were tracts from red blood cells from a mouse transgenic for (lane 1) entrapped, with a less dense and in some cases linear wild-type human SOD1, (lanes 2-4) G85R lines 148 (3 months old), 148 (10 months old), and 124 (10 months old), respectively, and (lanes 5 and 6) nontransgenic control mice. A series of 2-fold dilutions of purified human SOD1 were immunoblotted in parallel (lanes 7-10) to provide standards for quantitation.
(D) SOD1 activity in spinal cord extracts from 3-(lanes 4-7) and 10-(C) Total protein extracts from spinal cords of 1-, 3-, and 10-month-(lanes 8-11) month-old transgenic (lanes 5-7 and 9-11) and control old (top and middle lanes) G85R, line 148 mice and (bottom lane) (lanes 4 and 8) mice determined on native gels (as described by nontransgenic, control mice immunoblotted with antibodies recog- Beauchamp and Fridovich, 1971 ). Lanes 1-3: a 2-fold dilution series nizing an epitope specific for (top lane) human SOD1 or (middle and (0.5, 1, and 2 g) of human erythrocyte SOD1 used as quantitation bottom lanes) mouse SOD1.
standards.
array of filaments ‫01ف(‬ nm in diameter) at the periphery undergoing degeneration in ventral roots from animals before ( Figure 6C ), at ( Figure 6D ), and after ( Figure 6E ) of the inclusion. The absence of reactivity to GFAP antibodies except at the periphery ( Figures 3A and 3C) and appearance of clinical signs. Consistent with the earliest abnormalities in the spinal cord, no significant loss of the circumferential GFAP filaments observable at the edges of these aggregates strongly suggest that GFAP axons was detectable prior to clinical onset ( Figures 6A  and 6C ), although a small number (Ͻ1%) of large (Ͼ5 is not a major constituent of the filamentous material in the central domain of these aggregates. m in diameter) axons in motor roots showed degeneration at 6.5 months (coincident with the earliest spinal A second type of abnormality appearing prior to clinical onset was the presence in a small number of motor cord pathology). However, at the time of the first clinical signs, 25% of the large motor axons were missing (Figneurons of a few diffuse aggregates that were intensely immunoreactive both for SOD1 ( Figure 5B ) and ubiquitin ure 6A), and of the surviving axons, 10% were actively undergoing degeneration ( Figure 6B ; see also Figure 6D , (Figure 5A ), despite normal appearance by H and E staining. In contrast, the large majority of neurons as well as arrows). By the end of the 2 week clinical course, about two thirds of the large axons were absent, while 50% of nontransgenic neurons and all neurons of G85R animals at younger ages were unreactive with ubiquitin antibodthose remaining were degenerating ( Figure 6B ). Smaller caliber axons (Ͻ5 m in diameter) were not affected at ies, and these normal neurons displayed much less intense, diffuse, granular SOD1 immunoreactivity ( Figure  any stage of the disease ( Figure 6A ). Analysis of sensory axons in the dorsal root revealed that prior to clinical 5B, arrowheads), as previously reported . Abnormalities in motor neurons progressed from onset, sensory axons were unaffected, whereas at onset, 2.5% of large axons (Ͼ5 m in diameter) were acdiffusely localized SOD1-and ubiquitin-containing aggregates seen prior to clinical onset (Figures 5A and tively degenerating or lost, with a few large swollen axons ‫52ف(‬ m in diameter). The number of dorsal root 5B) to rounded (Lewy body-like) or irregular inclusions visible by H and E staining in cell bodies ( Figure 5C , axons either dying or lost increased to 7.5% of large axons at end stage. inset). At end stage, even larger inclusions could be found in a few neurons both in the cell bodies ( Figure  5E ) and in proximal axonal processes (Figures 5C and
Selective Loss of the Major Spinal Glutamate 5G). Like those in astrocytes, inclusions in neuronal cell
Transporter (GLT-1) during Disease bodies and swellings of proximal processes displayed Progression in G85R Mice intense SOD1-immunoreactivity ( Figure 5D ), both in the Excitotoxicity from excessive extracellular glutamate central core and periphery. In addition, the periphery, has been proposed as a factor in sporadic ALS, an but not the central domain, of each inclusion stained hypothesis arising from demonstration of increased cewith antibodies to ubiquitin ( Figure 5F ). Immunocytorebrospinal fluid concentrations of glutamate early in chemistry with antibodies to multiple neurofilament epithe clinical course of ALS (Rothstein et al., 1990) 
and topes (SMI-31, SMI-32, NF-H [not shown] and NF-L [Fig-
decreased glutamate transport in patients with sporadic ure 5H]) revealed that neurofilaments were excluded ALS (Rothstein et al., 1992) . Inactivation of glutamate is from all of these inclusions and swellings but were often accomplished by its removal from extracellular space found circumferentially around an inclusion. Vacuoles by glutamate transporters, three of which have been like those in cell bodies, dendrites, and axons of preidentified: GLT-1 (Pines et al., 1992) and GLAST (Storck viously reported transgenic mice expressing SOD1 muet al., 1992) found in glia (Rothstein et al., 1994b ) and tants G93A (Gurney et al., 1994) or G37R (Wong et al., EAAC1 (Kanai et al., 1993) found only in neurons 1995) were not seen at any point in disease, and mito- (Rothstein et al., 1994b) . To examine if diminished ability chondria appeared morphologically normal. Comparito sequester glutamate could be contributing to the son of spinal cord sections of nontransgenic control and rapid progression of G85R-mediated disease, we immuend-stage G85R animals revealed obvious loss of motor noblotted spinal cord homogenates from nontransgenic neurons in the ventral horn as the result of mutant SOD1 and G85R mice and measured each transporter with expression (not shown). specific antibodies (Rothstein et al., 1994b) . In four out Neuronal abnormalities were not limited to the ventral of four animals examined, there was a 50% decrease motor neuron populations but included small neurons in levels of the GLT-1 protein in spinal cord extracts near the central canal and rare interneurons of the dorsal from end-stage G85R mice (analyses of two of these horns. Studies, to be reported in detail elsewhere, of animals are presented in Figure 7B , lane 4) compared the remainder of the central nervous system revealed to G85R mice at 3 months ( Figure 7B , lane 3). Levels similar-appearing eosinophilic inclusions in brain stem of GLT-1 were constant in age-matched control mice neurons and astrocytes, most prominently in the pons.
( Figure 7 , lanes 1 and 2). Levels of EAAC1 and GLAST No abnormalities have been identified in the cortical or were below detection limits in spinal cords of normal and subcortical structures of the brain. G85R mice, although GLAST was detected in cerebellar homogenates and EAAC1 in hippocampal homogenates. Correlation of transporter activities and immuRapid, Nearly Synchronous Degeneration and Death of Large Motor Neurons noblotting of brain has previously shown that all three antibodies have comparable sensitivities in detecting Following Onset To examine the progression of ventral motor neuron the corresponding transporters (Rothstein et al., 1994b; . These findings indicate that GLT-1 is the major axonal degeneration, we counted the number of apparently healthy axons and the number of axons actively glutamate transporter in spinal cord and that there is aggregates remains unresolved. An additional key question not yet resolved is whether the SOD1 in these incluDiscussion sions represents the mutant subunit, endogenous SOD1, or a mixture of both. We have attempted to anWe have shown that low levels of accumulated human G85R SOD1 (between 0.2 and 1.0 ϫ the level of endogeswer this using peptide antibodies specific for human or mouse SOD1; however, they have failed to detect nous SOD1) are sufficient to cause severe motor neuron disease without altering the protein and activity levels the corresponding proteins by immunocytochemistry, despite repeated attempts and their high sensitivity on of endogenous SOD1. This level of human FALS-linked mutant SOD1 is ‫-02ف‬fold Ͻ the amount required to meimmunoblots. Since expression of wild-type SOD1 alone does not form such aggregates even at 12 ϫ the normal diate disease by two previously described human FALSlinked mutants, G93A (Gurney et al., 1994) and G37R level, it must be that the mutant protein induces aggregate formation. However, neither the level of endoge- , indicating that G85R is significantly more toxic, at least in mice. Moreover, the most striking nous mouse protein nor its activity in whole tissue extracts is altered even at end stage, indicating that overall finding in transgenic mice expressing human G85R SOD1 is the presence of numerous inclusions in degradation and activity of endogenous mouse SOD1 is not significantly affected by the presence of the mutant astrocytes that appear prior to similar inclusions in neurons. By end stage, when there is a 2-fold elevation in subunit. Of course, as both activity and protein levels of mouse and mutant SOD1 are measures of whole spinal SOD1 protein in whole spinal cord extracts and a 60% loss of large axons, inclusions are approximately 10 ϫ cord, we cannot exclude the possibility that there are regional differences in SOD1 activity and accumulation. more abundant in astrocytes than neurons, indicating that for this mutation, astroglia are a major target of Indeed, the SOD1-containing inclusions, primarily in astrocytes but also in motor neurons, offer direct experi-SOD1-mediated damage. Both the dense core and the periphery of both astrocytic and neuronal inclusions mental support for the possibility that toxicity of some SOD1 mutants may arise from mutant-mediated aggreshow high levels of SOD1 immunoreactivity. While no autopsy material is available for familial cases with the gation and the corresponding mislocalization of SOD1 (including local loss of activity). This cannot be the only G85R mutation (N. Siddique and T. Siddique, personal communication), neuronal SOD1-positive inclusions affect of the mutants, however, since complete loss of SOD1 does not result in motor neuron disease (Reaume have been described in some familial ALS patients with mutation A4V (Shibata et al., 1996) , and inclusions with et al. , 1996) . Central to understanding the mechanism of neuronal similar SOD1 immunoreactivity in astrocytes have also been reported in a familial ALS patient with a 2 bp deledeath in SOD1-linked familial ALS is the identity of the toxic property or properties that lead to familial ALS. tion in the 126th codon of SOD1 leading to a frameshift and truncation of the final 27 amino acids (Kato et al., One hypothesis put forward by Beckman and colleagues (Beckman et al., 1993) is that the mutant subunits unfold 1996). However, the demonstration here that SOD1-containing inclusions in astrocytes are early abnormalities slightly, allowing increased access of peroxynitrite (formed spontaneously from nitric oxide [NO] and superand increase markedly in abundance after disease onset provides strong support for the view that at least some oxide anion [O2 Ϫ ]) to the enzyme-bound copper, which in turn uses peroxynitrite to nitrate tyrosine residues on of the familial ALS-linked SOD1 mutants mediate disease by direct affects on astrocytes, in both human and proteins. A second hypothesis holds that the mutants catalyze the formation of hydroxyl radicals from hydromurine disease.
Although it is not obvious how inclusions originate, gen peroxide via a process called the Fenton reaction. Hydroxyl radicals have been proposed to damage a the finding that these inclusions contain abundant SOD1 polypeptides, both in the core and periphery, implicates variety of cellular targets including SOD1, mitochondrial membranes (via lipid peroxidation), and glutamate transaberrant accumulation of mutant protein, perhaps as a result of an altered conformation that resists the ubiquiporters (via oxidation) (Pogun et al., 1994) . In vitro, at least two mutations can increase the rate of hydroxyl tin-mediated degradation pathway. Whether toxicity (A and B) Lewy body-like cytoplasmic inclusions in astrocytes, consisting of a pale periphery and dense central core seen by (B) H and E as one of the earliest pathological findings in a 6-month-old transgenic mouse (line 148) expressing G85R SOD1. (A) The astrocytic nature of the cells that contain these inclusions is demonstrated by the peripheral, halo-like staining with antibodies to GFAP (arrow). Arrowhead points to a nucleus of an adjacent motor neuron. (C) Individual inclusions (H and E, inset) from an end-stage G85R animal, and destaining-restaining with (C) antibodies to GFAP reveals that the periphery of these inclusions are immunoreactive for GFAP. Open Arrow points to a reactive astrocyte. Arrowhead points to an adjacent motor neuron nucleus. radical formation, probably due to increased availability riod of G85R-mediated disease offers strong support for the idea that molecular targets exist within astrocytes of the active Cu 2ϩ site to H 2 O 2 (Wiedau-Pazos et al., 1996) . However, there is as yet no in vivo support (in that can be damaged by mutant SOD1. Dysfunction of astrocytes could have significant consequences. These human tissues or in mouse models) for either hypothesis. Moreover, that mice expressing G85R SOD1 differ cells provide molecules (e.g., trophic factors and nutrients, etc.) that crucial for neuronal viability (Oppenheim clinically (later onset plus rapid and synchronous motor neuron loss after onset) and pathologically (numerous et al., 1988; Lin et al., 1993) . Moreover, these cells influence the microenviroment in the neuropil through scavastroglial inclusions and absence of vacuoles) from G93A and G37R SOD1 mice may be explained by differenging of extracellular neurotransmitters, such as glutamate. The primary mechanism for the inactivation of ences 1) in the toxic properties of the mutants, such as preferential, conformation-dependent use of peroxide, glutamate is its removal from the extracellular space by glutamate transporters. One of these, GLT-1, is found peroxynitrite, or other abnormal substrates and 2) the specific vulnerabilities of different cell types (i.e., glia or only in glia (Rothstein et al., 1994b) . A second, GLAST, was initially thought to be present in glia and neurons neurons) to each mutant's toxic effects.
That SOD1-mediated damage to the astrocytes is the but more recently has been argued to be only in glia (Rothstein et al., 1996) , while the third, EAAC1, is found most prominent early abnormality in the preclinical pe- 
Experimental Procedures
only in neurons (Rothstein et al., 1994b) . We have shown here that GLT-1 is the most abundant glutamate trans-
Construction of Transgenic Mice Expressing Mutant
porter in spinal cords and that levels of it are decreased G85R Human SOD1 in end-stage G85R mice, a finding that is strikingly simiThe G85R mutation was engineered into the human SOD1 gene (a 12 lar to that observed in patients with sporadic ALS kb EcoRI-BamHI genomic DNA fragment) by PCR/oligonucleotide primer-directed mutagenesis strategy as described by Wong et al. . Moreover, loss of either glial (1995) , starting from a previously characterized plasmid, pHGSODtransporter, GLT-1 or GLAST, via chronic intraventric- SVneo (Epstein et al., 1987) encoding wild-type human SOD1. ular antisense oligonucleotide administration has been Transgenic founder mice were identified by blotting of DNA isolated shown to produce a progressive motor deficit in rats from mouse tail using a human SOD1 cDNA as a probe. (Rothstein et al., 1996) . Indeed, in these antisense experiments, obvious motor deficits arose when GLT-1 levels GPVKVWGSIK corresponding to residues 24-36 from human SOD1) nitrocellulose, and immunoblotted with an antibody specific for huor an antipeptide antibody generated against a man SOD1. sequence identical in human and mouse SOD1 (CYDDLGKGGNEE STK corresponding to residues 124-136). Bound primary antibody Measurement of SOD1 Activity was detected with 125 I-labeled protein A. Quantitation was achieved The spinal cords from control and transgenic mice were homogeby immunoblotting a dilution series of known amounts of purified nized in buffer containing 20 mM Tris-HCl (pH 7.2), 1 mM EDTA, human erythrocyte SOD1 (Sigma, St. Louis) in parallel. Signals were and 1% Triton X-100. After centrifugation at 10,000 ϫ g for 5 min, quantified using a Molecular Dynamics Phosphorimager (Sunnyvale, the supernatant was electrophoresed on a 7.5% polyacrylamide California).
gel, and SOD1 activities were determined as previously reported (Beauchamp and Fridovich, 1971 ).
Detection of Blood SOD1
Blood from nontransgenic mice, mice expressing wild-type human Measurement of Levels of Glutamate Transporters SOD1, and G85R transgenic mice was hemolyzed, extracted with GLT-1, GLAST, and EEAC1 ethanol and chloroform (L'Abbe and Fischer, 1990), and clarified by Extracts of whole spinal cord from control and transgenic mice centrifugation at 10,000 ϫ g. The supernatant (red blood cell lysate) was electrophoresed on a 15% polyacrylamide gel, transferred onto were prepared as described above and electrophoresed on 7.5% peroxide, rinsed in phosphate-buffered saline, and incubated overnight in the primary antibody. Immunoreactivity was visualized with diaminobenzidine, and sections were counterstained with hematoxylin. For characterization of inclusion bodies, H and E-stained sections of spinal cords from end-stage animals were examined and photographed by light microscopy. Coverslips were removed, slides were rinsed in xylene, 100%, 95%, and 70% alcohol, decolorized with 1% HCl in 70% ethanol for a few minutes, and stained by standard immunocytochemical methods.
Electron Microscopy
Spinal cords and roots were dissected from transcardially perfused animals and postfixed in 4% paraformaldehyde and 1% gluteraldehyde. Subsequently, tissues were incubated in 2% osmium tetroxide in 0.05 M cacodylate for 3.5 hr, washed, dehydrated, and embedded in Epon-Araldite resin (Ernest F. Fullam, Inc., Latham, New York). Thick (0.75 m) sections stained with toludine blue were examined by light microscopy, while thin (70 nm) sections were stained with lead citrate-uranyl acetate and examined by electron microscopy.
Quantitation of Motor Neuron Degeneration
Large (Ͼ5 m diameter) and small (Ͻ5 m diameter) axons were counted in cross sections of L4 ventral roots from transgenic mice at 3.5, 4.5, and 6.5 months of age, as well as transgenic mice showing the first signs of hindlimb weakness and at end-stage disease. The number of surviving axons was determined as a percentage of the total number of large or small axons in an average of five control mice. The number of degenerating axons was determined as a percentage of the total number of surviving (both healthy and degenerating) axons. Two animals were used for each time point.
